tpan.com: What's PK Got to Do With It? Table 2

Table No. 2: Antiretroviral Regimens Recommended for Treatment of HIV-1 Infection in Antiretroviral Naïve Patients
	Regimens	No. of pills
Preferred Regimens
NNRTI-based	Sustiva + (Epivir or Emtriva) + (Retrovir or Viread) (AII) – [Note: Sustiva is not recommended for use in first trimester of pregnancy or in women with high pregnancy potential*]	2-3
PI-based	Kaletra (lopinavir/ritonavir co-formulation) + (Epivir or Emtriva) + Retrovir (AII)	8-9
Alternative Regimens
NNRTI-based	Sustiva + (Epivir or Emtriva) + (Ziagen or Videx or Zerit) (BII) – [Note: Sustiva is not recommended for use in first trimester of pregnancy or in women with high pregnancy potential*]	2-4
Viramune + (Epivir or Emtriva) + (Retrovir or Zerit or Videx or Ziagen or Viread) (BII) - [Note: High incidence (11%) of symptomatic hepatic events observed in women with pre-Viramune CD4 + T cell count more than 250 cells/mm1 and men with CD4 more than 400 cells/mm1 (6.3%). Use with caution in these patients, with close clinical laboratory monitoring, especially for the first 18 weeks of therapy]	3-6
PI-based	Reyataz + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Videx) or (Viread + Norvir 100 mg/d) (BII)	3-6
Lexiva + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Viread or Videx) (BII)	5-8
Lexiva/Norvir + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Viread or Videx) (BII)	5-8
Crixivan/Norvir + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Viread or Videx) (BII)	7-12
Kaletra + (Epivir or Emtriva) + (Zerit or Ziagen or Viread or Videx) (BII)	7-10
Viracept + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Viread or Videx) (CII)	5-8
Fortovase (SGC) or Invirase (HCG) / Norvir + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Viread or Videx) (BII)	13-16
3 NRTI-based	Ziagen + Retrovir + Epivir – only when a preferred or an alternative NNRTI- or a PI-based regimen cannot or should not be used (CII)	2
* Women with child-bearing potential implies women who want to conceive or those who are not using effective contraception. Source: www.hivatis.org

Regimens

No. of pills

Preferred Regimens

NNRTI-based

Sustiva + (Epivir or Emtriva) + (Retrovir or Viread) (AII) – [Note: Sustiva is not recommended for use in first trimester of pregnancy or in women with high pregnancy potential*]

2-3

PI-based

Kaletra (lopinavir/ritonavir co-formulation) + (Epivir or Emtriva) + Retrovir (AII)

8-9

Alternative Regimens

NNRTI-based

Sustiva + (Epivir or Emtriva) + (Ziagen or Videx or Zerit) (BII) – [Note: Sustiva is not recommended for use in first trimester of pregnancy or in women with high pregnancy potential*]

2-4

Viramune + (Epivir or Emtriva) + (Retrovir or Zerit or Videx or Ziagen or Viread) (BII) - [Note: High incidence (11%) of symptomatic hepatic events observed in women with pre-Viramune CD4 + T cell count more than 250 cells/mm1 and men with CD4 more than 400 cells/mm1 (6.3%). Use with caution in these patients, with close clinical laboratory monitoring, especially for the first 18 weeks of therapy]

3-6

PI-based

Reyataz + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Videx) or (Viread + Norvir 100 mg/d) (BII)

3-6

Lexiva + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Viread or Videx) (BII)

5-8

Lexiva/Norvir + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Viread or Videx) (BII)

5-8

Crixivan/Norvir + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Viread or Videx) (BII)

7-12

Kaletra + (Epivir or Emtriva) + (Zerit or Ziagen or Viread or Videx) (BII)

7-10

Viracept + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Viread or Videx) (CII)

5-8

Fortovase (SGC) or Invirase (HCG) / Norvir + (Epivir or Emtriva) + (Retrovir or Zerit or Ziagen or Viread or Videx) (BII)

13-16

3 NRTI-based

Ziagen + Retrovir + Epivir – only when a preferred or an alternative NNRTI- or a PI-based regimen cannot or should not be used (CII)

2

* Women with child-bearing potential implies women who want to conceive or those who are not using effective contraception. Source: www.hivatis.org